Below is a list of the medicines Lilly currently markets in Canada, and the product monographs (a scientific document that describes the medication’s properties, claims, indications, conditions of use and safety information). Customer manuals for our devices are also available for download on this page.
Please note that Canadian laws and regulations limit the amount of information on our products that we can provide to the general public via our website and/or by other means. We encourage consumers wishing to obtain more detailed information on our products to speak to their health care professional or to contact the Lilly Customer Response Centre at 1-888-545-5972.
The product information on this web site is intended for residents of Canada only.
| Product | Product Monograph | User Manual | Additional Information |
AdcircaTM (tadalafil) |  | ||
| Alimta® (pemetrexed) | | ||
| Cialis® (tadalafil) | | ||
Cymbalta® (duloxetine hydrochloride) | | ||
| EffientTM (prasugrel hydrochloride) | | ||
| Evista® (raloxifene hydrochloride) | | ||
| Forteo® (teriparatide (rDNA origin) injection) | | | |
| Gemzar® (gemcitabine hydrochloride) | | ||
| Glucagon® (glucagon for injection, rDNA origin) | | ||
| Humalog® (insulin lispro for injection) Humalog® Mix25 (25% insulin lispro injection, 75% insulin lispro protamine suspension) Humalog® Mix50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) | | ||
| HumaPen® Ergo HumaPen® Luxura™ HumaPen® Luxura™ HD HumaPen® Memoir™ | | Health Care Professional Letter Health Care Professional Letter Public Communication Public Communication | |
| Humatrope® (somatropin for injection) | | ||
| Humulin® (insulin, human biosynthetic) Humulin® N (insulin isophane (rDNA origin)) NPH Humulin® R (insulin injection (rDNA origin)) Regular Humulin® 30/70 (30% insulin injection, 70% insulin isophane (rDNA origin)) | | ||
| Prozac® (fluoxetine hydrochloride) | | Health Care Professional Letter | |
| Reopro® (abciximab) | | ||
| Strattera® (atomoxetine) | | Health Care Professional Letter Health Care Professional Letter Health Care Professional Letter Public Communication Public Communication Public Communication | |
| Xigris® (drotrecogin alpha (activated)) | | Notice to Hospitals Health Care Professional Letter Notice to Hospitals | |
| Zyprexa® (olanzapine) Zyprexa® Zydis®* Zyprexa® IntraMuscular (olanzapine tartrate for injection) | | Health Care Professional Letter Public Communication |
Permax® Public Communication
*Important Note: You must have Acrobat Reader version 4.0 or higher installed to view these files. If you have an earlier version installed, an update is available from the Adobe Acrobat Reader download site.
® Registered trademark owned by Eli Lilly and Company; used under license.
TM Trademark owned by Eli Lilly and Company; used under license.
®*Zydis is a trademark owned by R.P. Scherer Technologies, Inc., a Catalent Pharma Solutions Company
